人工肝治疗肝衰竭模式选择及其疗效判断标准  

Model selection and curative effect judgment criteria for artificial liver in the treatment of liver failure

作　　者：周莉[1] 陈煜[1] Zhou Li;Chen Yu(Fourth Department of Liver Disease,Beijing You'an Hospital,Capital Medical University,Beijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research,Beijing 100069,China)

机构地区：[1]首都医科大学附属北京佑安医院肝病中心四科(疑难肝病及人工肝中心),肝衰竭与人工肝治疗研究北京市重点实验室,北京100069

出　　处：《中华肝脏病杂志》2022年第2期127-130,共4页Chinese Journal of Hepatology

基　　金：大数据精准医疗高精尖创新中心(PXM2021_014226_000026);首都卫生发展科研专项项目(2021-1G-2181)。

摘　　要：人工肝是治疗肝衰竭的有效方法之一。肝衰竭患者病情危重、病情个体化差异较大,人工肝治疗肝衰竭的具体方案应个体化。常用的非生物型人工肝模式包括单纯血浆置换、双重滤过血浆置换、血浆透析滤过、双重血浆分子吸附系统、分子吸附再循环系统、血液透析滤过、连续性静脉-静脉血液透析滤过.组合模式人工肝治疗等。在人工肝治疗后,应从患者症状、实验室检查指标、生存率等方面对其疗效做出恰当的判断。Artificial liver is one of the effective methods to treat liver failure.Patients with liver failure are critically ill and have great individualized differences.Therefore,the specific program for the treatment of liver failure with artificial liver should be individualized.The commonly used non-biological artificial liver models include simple plasmapheresis,double filtration plasmapheresis,plasma filtration with dialysis,double plasma molecular adsorption system,molecular absorbent recirculating system,hemodiafiltration,continuous venovenous hemodiafiltration,hybrid,etc.The curative effect should be properly judged from patient’s symptoms,laboratory test indicators,survival rate and other aspects after artificial liver therapy.

关 键 词：人工肝 肝衰竭 治疗 疗效 组合模式 

分 类 号：R575.3[医药卫生—消化系统]